Key Highlights
- Carcinotech’s Carcino3D technology: Revolutionizes cancer treatment with 3D printed micro-tumors, simulating the tumor microenvironment for enhanced drug testing.
- Strategic partnerships: Collaboration with CELLINK and support from Eos Advisory and other notable investors bolster Carcinotech’s position in the oncology sector.
- Leadership and vision: CEO Ishani Malhotra’s commitment to personalized medicine and the establishment of a strong scientific and advisory board signify Carcinotech’s dedication to pioneering oncology drug development.
Source: Business Wire
Notable Quote
- “Our vision is to be at the forefront of cancer drug testing and provide personalized medicine testing to every individual suffering from cancer to improve their treatment and chance of survival. Working with global partners, leading pharma companies, surgeons, pathologists, and clinicians, Carcinotech aims to significantly accelerate oncology drug development.” – Ishani Malhotra, CEO and Founder at Carcinotech
SoH's Take
Carcinotech’s recent funding milestone is not just a testament to its groundbreaking Carcino3D technology but also a beacon of hope in the precision medicine landscape. By simulating real tumor environments, Carcinotech is not only pushing the boundaries of personalized cancer treatment but also ensuring that the path to recovery becomes more attainable and tailored for each patient. With the robust support from industry veterans and strategic partnerships, Carcinotech is well-positioned to lead the charge in revolutionizing cancer drug development, offering a glimmer of hope in a domain where every second and every breakthrough counts profoundly.
